Nivolumab-related lichen planus of the lip in a patient with head and neck cancer
- 3 March 2020
- journal article
- letter
- Published by Elsevier BV in Oral Oncology
- Vol. 104, 104623
- https://doi.org/10.1016/j.oraloncology.2020.104623
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Linear bullous lichen planus associated with nivolumabClinical and Experimental Dermatology, 2018
- Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expressionOral Oncology, 2018
- Nivolumab reactivation of hypertrophic lichen planus, a case report and review of published literature.Dermatology Online Journal, 2018
- Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal TractFrontiers in Immunology, 2017
- Oral lichenoid reactions associated with anti‐PD‐1/PD‐L1 therapies: clinicopathological findingsJournal of the European Academy of Dermatology and Venereology, 2017
- Lichen Planus in Irradiated Skin During Nivolumab TreatmentActa Dermato-Venereologica, 2017
- Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic FeaturesThe American Journal of Dermatopathology, 2017
- Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 ImmunotherapyJAMA Dermatology, 2016
- Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapyEuropean Journal Of Cancer, 2016
- Practical Management of Immune-Related Adverse Events from Immune Checkpoint Protein Antibodies for the OncologistAsco Educational Book, 2012